efalizumab trade name raptiva genentech merck serono formerly available medication designed treat autoimmune diseases originally marketed treat psoriasis implied suffix zumab recombinant humanized monoclonal antibody administered weekly subcutaneous injection efalizumab binds subunit lymphocyte functionassociated antigen acts immunosuppressant inhibiting lymphocyte activation cell migration blood vessels tissues efalizumab associated fatal brain infections withdrawn market known side effects include bacterial sepsis viral meningitis invasive fungal disease progressive multifocal leukoencephalopathy pml brain infection caused reactivation latent jc virus four cases pml reported plaque psoriasis patients incidence approximately one treated due risk pml european medicines agency fda recommended suspension market european union united states april genentech inc announced phased voluntary withdrawal raptiva us immune activation dostarlimab ibalizumab monoclonal article stub help wikipedia expanding antineoplastic immunomodulatory drug article stub help wikipedia expanding httpsenwikipediaorgwikiefalizumab